Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT04399603 |
| Other study ID # |
283783 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
June 1, 2020 |
| Est. completion date |
December 31, 2024 |
Study information
| Verified date |
March 2024 |
| Source |
Imperial College London |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
In the United Kingdom, there are currently 138,000 confirmed patients with coronavirus,
causing 18,738 deaths. Whilst the disease may be mild in the majority of patients, a
significant proportion of patients require intensive care therapy and a ventilator due to
lung injury. In addition to lung injury/failure (acute respiratory distress syndrome (ARDS)),
around 50% of patients admitted to intensive care develop acute kidney injury (AKI)
(requiring advanced support via haemofiltration) and multi-organ failure.
It is unclear why patients suffering from COVID-19 develop such severe lung injury (requiring
life support or ventilation) or indeed why patients develop other organ dysfunction such as
kidney injury. The investigators hypothesis that this may due to an over-reaction of the
immune system particularly in the lungs. This then results in the release of various
mediators and biological messengers which can be pushed into the blood bloodstream
(exacerbated by positive pressure generated by the ventilator). These mediators then travel,
via the blood, to other organs such as the kidney where they cause inflammation and injury of
cells, resulting in organ failure.
The investigators would like to apply their well-established laboratory methods to further
the scientific community's knowledge of this severe and deadly viral condition and we hope
that this would lead to the development of medication that would treat this deadly virus.
Description:
COVID-19 is a highly contagious virus, causing a global health emergency. A significant
number (~17%) of hospitalised patients become severely unwell and require admission to an
intensive care unit (ICU) due to lung failure (acute respiratory distress syndrome (ARDS))
and multi-organ failure (MOF). Sadly, 51.8% of COVID-ARDS patients develop kidney failure,
which has a markedly increased risk of dying (61%). We have learned that kidney failure
starts several days after lung failure, which suggest an initial viral "attack" on the lungs
followed by kidney involvement several days later.
Cytokines are "signalling" molecules made by cells, which in healthy individuals help fight
disease. It was initially thought that in COVID-19, lung cells release excessive cytokines
(i.e. cytokine storm), which then cause kidney injury and MOF. However, research has
demonstrated that cytokine levels in blood are actually very low and not enough to explain
the extent of organ injury in COVID-19. This perhaps explains why treatment strategies aimed
at specifically damping down the action of these particular cytokines in COVID-19 have
failed. Consequently, there remains no cure for COVID-19 MOF, and whilst treatments such as
steroids, manage symptoms, have a general anti-inflammatory effect and improve mortality, 30%
of intensive care patients still die. Therefore, urgent research is needed to improve
scientific knowledge of this condition and identify new therapies.
Microvesicles (MVs) are extremely small particles released by cells and carry various
chemicals including cytokines, from inside the cell, packaged securely and safely within
membranes (cellular envelopes). These vesicles act as 'postmen' delivering chemical
messengers (e.g. cytokines) between cells and are important in various diseases where
inflammation is implicated. The investigators have demonstrated that MVs have a fundamental
role in the development of organ failure in laboratory models of non-COVID ARDS but the
investigators do not yet know the role of these vesicles in the development of ARDS/MOF in
COVID-19.
The investigators hypothesise that during COVID-19 infection of the lung, significant numbers
of MVs are released within the lung (especially in severe COVID-19), which then "transmit"
signals and inflammation to other organs via the bloodstream, causing organs to fail.
Furthermore, as chemical messengers (e.g. cytokines) are hidden inside these vesicles, they
are not measured by standard laboratory techniques and may explain why there are low cytokine
levels in blood. This may also clarify why treatments inhibiting circulating cytokines (not
hidden in vesicle membranes) have failed.
To explore these ideas, the group aim to investigate MVs in blood and urine of ICU patients
with severe COVID-19 (20mls blood (1 1/3 tablespoons); 10ml urine (3/4 tablespoon)). The
investigators intend to examine which chemicals are present in these tiny vesicles and to
relate this information to the clinical progress or otherwise of patients. These data will
help the scientific community understand the chemical systems involved in severe COVID-19,
tell us the significance of MVs and whether blocking MV signalling could lead to new
treatments for COVID-19. Furthermore, analysis of these MVs may allow the investigators to
identify patients who are likely to become seriously ill, which would help in planning
treatment.
